Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1139 in Healthy Participants
NCT07078695Phase 1Active, not recruiting
- Sponsor
- Atridia Pty Ltd
- Start
- Aug 2025
- Primary completion
- Sep 2026
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of SHR-1139 in psoriasis (3 arms), sponsored by Atridia Pty Ltd. Primary endpoints: Pharmacokinetic profile of SHR-1139 at Day 253 and Immunogenicity profile of SHR-1139 at Day 253. Started Aug 2025; status: active, not recruiting.
02
Drugs
SHR-1139
03
Conditions
psoriasis
Beyond the preview
Go deeper on NCT07078695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07078695.